Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tersera Therapeutics LLC holds a company patent portfolio with 1 pending office action. This action is assigned to 1 distinct examiner, NATARAJAN, MEERA. The data does not specify a technology area for this portfolio, and it currently shows 0 distinct art units, indicating a narrow prosecution profile. NATARAJAN, MEERA is the busiest examiner with 1 pending office action.
Since there is only 1 pending office action in the entire portfolio, this examiner manages the totality of the company's current pending workload. Practitioners can observe that the prosecution is currently limited to 1 point of contact at the office. This centralized approach means that all current patent office interactions for the company are filtered through the assigned examiner. The current state of the portfolio suggests a focused prosecution phase, especially as the data shows 0 distinct art units are currently active.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18394869 | HER2/neu-Specific Antibodies and Methods of Using Same | NATARAJAN, MEERA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18394869 | HER2/neu-Specific Antibodies and Methods of Using Same | NATARAJAN, MEERA | — | §103DP | Non-Final OA | — | Pending | Dec 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial